LIMN Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -67.56%, SMA50 -68.19%, SMA200 -94.14%). The stock’s 14-day RSI is 36.82 (weak momentum), while the ATR of 0.23 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -99.32% below its high and over 9.48% above its low. Average 10-day trading volume of 11.24 million shares is slightly above the 3-month average of 9.62 million, indicating heightened recent market interest.

Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) closed at $0.13 USD, gaining $0.02 (13.59%) from the previous close of $0.11. The stock is currently mid-range between its 52-week high and low $0.10 and $10.20. With a market capitalization of about $3.50 million, Liminatus Pharma, Inc. Class A Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.70). Key stats such as the average daily volume over the past year has been around 11.86 million shares, trading with heavier-than-usual volume. Headquartered in La Palma, CA, Liminatus Pharma, Inc. Class A Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Chris Kim, the company employs approximately 3 people and listed since May 01, 2025. Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer.

Liminatus Pharma, Inc. Class A Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.05. This means the shares are trading below this model’s fair value.

Liminatus Pharma, Inc. Class A Common Stock (NASDAQ:LIMN) shares are up 19.67% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Liminatus Pharma, Inc. Class A Common Stock trading at a premium to the broader market with a P/E of -0.29. Our AI forecast model points to short-term weakness (-30.31% over two weeks), a medium-term fall (-56.45% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Liminatus Pharma, Inc. Class A Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -30.31%, with price expected at $0.08 by July 15, 2026, within a range of $0.07 to $0.10 3-Month Outlook: Projected fall of -56.45%, reaching $0.05 by September 29, 2026, with a range of $0.00 to $0.34. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 01, 2027, within a range of $0.00 to $0.45.

Liminatus Pharma, Inc. Class A Common Stock trades at a P/E ratio of -0.29, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -21.3 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.27, also above market averages.